Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,755.20
(
-0.17%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.43
(
-2.02%
)
Bitcoin
69,826.50
(
-1.97%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1749
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: DewDiligence post# 124826

Tuesday, 08/09/2011 1:30:46 PM

Tuesday, August 09, 2011 1:30:46 PM

Post# of 257262

INHX is running a genotype-2/3 phase-2 trial of INX-189:





INHX's strategy is the polar opposite of IDIX's kitchen sink strategy. Where INHX is focusing on two HCV subgroups using one class of drug IDIX now has IDX-184 (nuke), (2) preclinical nukes, a protease inhibitor, and a NS5A inhibitor under development. Not only does this undermine investor confidence in IDX-184 but how are they going to pay for all these programs?
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now